Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...

South Carolina prosecutors oppose Alex Murdaugh's push for independent DNA testing of evidence found under Maggie Murdaugh's ...

Wistar scientists developed a single-dose DNA method that delivers long-acting weight loss and diabetes drug effects in ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

The FDA could approve the first blood test that can detect multiple cancers, around the end of the year, setting the stage ...

Foundation Medicine tallied another nod from the FDA for one of its genomic profiling tests that searches for specific biomarkers in tumor tissue samples. () Foundation Medicine tallied another nod ...

Coverage on Pfizer is broad and divided, leaning toward cautious optimism. On average, analysts recommend holding shares, and they have a $29.19 consensus price target. Recent actions paint the same ...

The National Comprehensive Cancer Network recommends germline genetic testing for patients with prostate cancer and high-risk features or a suggestive family history. In 2024, the University of ...

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

A new prime assembly technique inserts DNA segments up to 11,000 base pairs into the genome, enabling correction of thousands of mutations at once. Reporting in Nature ("Prime assembly with linear DNA ...

New technology enables the insertion of a large segment of DNA into a genome, potentially expanding gene therapy treatment from cancellation of disease-causing mutations to replacement of an entire ...

The company releases its Q1 earnings on May 5th, in less than 2 weeks, so I think it's time for me to update my reasoning and take a look at what's coming next for PFE. First off, let me briefly ...